Department of Pharmaceutical Medicine (Division of Pharmacology), School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Independent Researcher, New Delhi, India.
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1595-1602. doi: 10.1016/j.dsx.2020.08.014. Epub 2020 Aug 20.
BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) spreads rapidly and within no time, it has been declared a pandemic by the World Health Organization. Evidence suggests diabetes to be a risk factor for the progression and poor prognosis of COVID-19. Therefore, we aimed to understand the pooled prevalence of diabetes in patients infected with COVID-19. We also aimed to compute the risk of mortality and ICU admissions in COVID-19 patients with and without diabetes.
A comprehensive literature search was performed in PubMed to identify the articles reporting the diabetes prevalence and risk of mortality or ICU admission in COVID-19 patients. The primary outcome was to compute the pooled prevalence of diabetes in COVID-19 patients. Secondary outcomes included risk of mortality and ICU admissions in COVID-19 patients with diabetes compared to patients without diabetes.
This meta-analysis was based on a total of 23007 patients from 43 studies. The pooled prevalence of diabetes in patients infected with COVID-19 was found to be 15% (95% CI: 12%-18%), p = <0.0001. Mortality risk was found to be significantly higher in COVID-19 patients with diabetes as compared to COVID-19 patients without diabetes with a pooled risk ratio of 1.61 (95% CI: 1.16-2.25%), p = 0.005. Likewise, risk of ICU admission rate was significantly higher in COVID-19 patients with diabetes as compared to COVID-19 patients without diabetes with a pooled risk ratio of 1.88 (1.20%-2.93%), p = 0.006.
This meta-analysis found a high prevalence of diabetes and higher mortality and ICU admission risk in COVID-19 patients with diabetes.
2019 年冠状病毒病（COVID-19）传播迅速，世界卫生组织（WHO）很快宣布其为大流行。有证据表明，糖尿病是 COVID-19 进展和预后不良的一个危险因素。因此，我们旨在了解 COVID-19 患者中糖尿病的总患病率。我们还旨在计算有和没有糖尿病的 COVID-19 患者的死亡率和 ICU 入院风险。
我们在 PubMed 上进行了全面的文献检索，以确定报告 COVID-19 患者糖尿病患病率和死亡率或 ICU 入院风险的文章。主要结局是计算 COVID-19 患者中糖尿病的总患病率。次要结局包括与无糖尿病的 COVID-19 患者相比，有糖尿病的 COVID-19 患者的死亡率和 ICU 入院风险。
这项荟萃分析基于来自 43 项研究的 23007 名患者。结果发现，感染 COVID-19 的患者中糖尿病的总患病率为 15%（95%CI：12%-18%），p<0.0001。与无糖尿病的 COVID-19 患者相比，有糖尿病的 COVID-19 患者的死亡率风险显著更高，合并风险比为 1.61（95%CI：1.16-2.25%），p=0.005。同样，与无糖尿病的 COVID-19 患者相比，有糖尿病的 COVID-19 患者的 ICU 入院率风险显著更高，合并风险比为 1.88（1.20%-2.93%），p=0.006。
这项荟萃分析发现，COVID-19 患者中糖尿病的患病率较高，且糖尿病患者的死亡率和 ICU 入院风险较高。
Zotero 插件
